comparemela.com

Latest Breaking News On - Seroba life - Page 1 : comparemela.com

Complement Therapeutics Secures €72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases

/PRNewswire/ Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases,.

United kingdomUnited statesDmitrij hristodorovRafiq hasanRoger franklin hadeanRob woodmanUnited states complement therapeutics incUnited kingdom complement therapeutics ltdRegulatory agencyUniversity of manchesterSeroba life sciencesHadean venturesSeroba lifeGeograpic atrophyComplement precision medicineInnovation passport

Complement Therapeutics Raises €72M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomRob woodmanRoger franklin hadeanRafiq hasanSeroba life sciencesComplement therapeuticsHadean venturesSeroba lifeRoger franklinGeograpic atrophyPrecision medicineComplement precision medicine

Shorla wins FDA approval for leukaemia drug

Clonmel-headquartered Shorla specialises in developing innovative oncology drugs, with a focus on orphan and paediatric cancers.

United statesOrlaith ryanSharon cunninghamShorla pharmaDrug administrationChildhood cancer researchSeroba life sciencesShorla oncologyNelarabine injectionStephenp hungerSeroba life

Coave Therapeutics Strengthens Board of Directors

- Frederic Chereau named Chairman of the Board - Seasoned entrepreneur, Dr Claudia Mitchell, appointed Non-executive Director PARIS, Oct. 20, 2022 /PRNewswire/ Coave Therapeutics

United statesFrance generalHaute normandieFranche comtérEleanor perkinOlivier danosWillem broekaertSylvie berrebiBruno montanariClaudia mitchellKostenloser wertpapierhandelAstellas pharmaThierry laugelGuillaume blavierFrederic chereauPhilippe monteyne

Advertiser ie - Galway-based neurovascular company Perfuze raises €22 5m Series A investment for new stroke treatment

Perfuze, a Galway-based medical device company developing next-generation catheter-based aspiration technology to treat large vessel occlusion acute ischemic stroke, has closed a €22.5 million Series A investment round.

Daniel omahonyMegan macdonaghAnne portwichDwayne allenHealth economics fundPartner at seroba life sciencesSv health investorsMedtech convergence fundSv healthSeroba life sciencesEconomics fundSeroba lifeMedfocus fundEnterprise irelandDanielo mahonySenior associate

vimarsana © 2020. All Rights Reserved.